Chris Sandburg
Recent Articles by Chris Sandburg
- RISE of the COVID-19 Therapeutics CytoDyn (OTCMKTS: CYDY) & Humanigen (NASDAQ:HGEN)
- CytoDyn (OTCMKTS: CYDY) Subtly Signals Pivot Into Philippines and Vaccine Market
- CytoDyn (OTCMKTS: CYDY) Accelerates Recruitment to 250 Patients in Pivotal COVID-19 Trial
- Handicapping CytoDyn’s (OTCMKTS: CYDY) Interim Readout
- CytoDyn (OTCMKTS:CYDY) May Make the White House Podium
- Wading through the STAT News FUD Attack on CytoDyn Inc. (OTCMKTS: CYDY)
- Fintech Rollup Xalles (OTCMKTS: XALL) Shocks Street with Acquisition that Doubles Revenues
- CytoDyn’s (OTCMKTS: CYDY) Strong Safety Data in Mild to Moderate Smokes Gilead (NASDAQ: GILD) & Crushes Endpoint Leading to the First Potential COVID-19 Approval
- FingerMotion (OTCMKTS: FNGR) Enters Big Data Space Solving Huge Inefficiencies in InsureTech Like IPO Darling Lemonade (NASDAQ: LMND)
- CytoDyn (OTCMKTS: CYDY) Bolts Higher On Mexican Approval Chatter